Why CMS’s Quiet Shift Toward Real-World Evidence Matters for Pharma Strategy

Why CMS’s Quiet Shift Toward Real-World Evidence Matters for Pharma Strategy

A recent Endpoints News article highlights a subtle but important shift in how the Centers for Medicare & Medicaid Services (CMS) is approaching the next phase of the Inflation Reduction Act (IRA): a growing openness to real-world evidence (RWE).

While this may seem like a technical policy evolution, it has significant implications for how pharmaceutical companies define value, plan evidence generation, and ultimately bring therapies to market.

For decades, randomized controlled trials (RCTs) have been the gold standard for demonstrating efficacy and safety. But they are not designed to fully capture how therapies perform in routine clinical practice. RWE—drawn from sources such as electronic health records, claims data, and patient registries—offers a more complete picture, reflecting real-world usage, broader patient populations, and long-term outcomes.

CMS’s increasing interest in RWE signals that future IRA negotiations and value assessments may rely more heavily on this type of evidence. That shift raises a critical strategic question: are companies defining the right real-world evidence early enough to support differentiation when it matters most?

Too often, RWE is treated as a downstream activity—something to be layered on after pivotal trials are complete or once a product is already on the market. But in an environment where payers and policymakers are increasingly focused on real-world value, this approach is no longer sufficient.

Instead, companies need to think about RWE much earlier in the asset lifecycle. Defining what evidence will be required—and how it will be generated—should be part of the broader path-to-market strategy from the outset. This includes identifying the key comparators, patient populations, and outcomes that will be most relevant not only to clinicians, but also to payers and decision-makers like CMS.

At IDEA Pharma, this is a core part of how we support our clients. We work with teams early to define the evidence strategy that will underpin differentiation, ensuring that RWE is not an afterthought but an integrated component of the overall asset plan. That means aligning evidence generation with future pricing, access, and policy considerations—well before those discussions formally begin.

In practice, this involves prioritising the types of RWE that will meaningfully influence decision-making: comparative effectiveness in real-world populations, durability of response, healthcare resource utilisation, and patient-relevant outcomes. It also means designing studies and data strategies that can deliver robust, credible insights at the right time in the product lifecycle.

The potential expansion of IRA considerations into Medicare Part B therapies further increases the urgency of this approach. Many oncology treatments—an area where IDEA Pharma works extensively with clients—fall into this category. If CMS applies similar evidence expectations here, companies will need to demonstrate not just clinical efficacy, but real-world performance relative to existing standards of care.

This makes early, strategic RWE planning essential for successful market access.

Ultimately, CMS’s pivot toward real-world evidence reflects a broader shift: value is increasingly being assessed in the context of real-world use, not just clinical trial conditions. For pharmaceutical companies, this is both a challenge and an opportunity.

Those that define and invest in the right RWE early—embedding it into their path-to-market strategy—will be better positioned to demonstrate value, support pricing, and achieve meaningful differentiation.

At IDEA Pharma, this is exactly where we focus: helping clients define the evidence that matters, early enough for it to shape the outcome.